Skip to Main Content

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

Principal Investigator

David Baidal

Clinical Trial ID

Institutional Protocol # 20180482
National Clinical Trials Identifier NCT03428945

Clinical Trial Summary


Phase 2

Funding Agency/Sponsor



Enrollment Eligibility

Inclusion Criteria:
1. Participant in TrialNet Pathway to Prevention Study (TN01)
2. Age 3 years or greater at the time of randomization
3. Willing to provide informed consent
4. Normal glucose tolerance by OGTT within 7 weeks (no more than 52 days) of baseline
5. Two or more diabetes-related autoantibodies present on two separate samples
6. Weight of 12 kg or greater at screening
7. If a female participant with reproductive potential, willing to avoid pregnancy and
undergo pregnancy testing prior to randomization and at each study visit
8. Anticipated ability to swallow study medication.
Exclusion Criteria:
1. Abnormal Glucose Tolerance or Diabetes
2. History of treatment with insulin or other diabetes therapies
3. Ongoing use of medications known to influence glucose tolerance
4. Ongoing or anticipated future use of medications known to have untoward interactions
with hydroxychloroquine
5. Known hypersensitivity to 4-aminoquinoline compounds
6. G6PD deficiency
7. History of retinopathy
8. Have an active infection at time of randomization
9. Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B
core antibody or surface antigen), or Hepatitis C infection
10. Deemed unlikely or unable to comply with the protocol or have any complicating medical
issues, including prolonged QT interval, a disease previously or likely in the future
to require immunosuppression, or abnormal clinical laboratory results that interfere
with study conduct or cause increased risk.

Contact Information

Study Contact Lisa Rafkin
Phone Number 305-243-6146
Get detailed information on ClinicalTrials.Gov